NINGBO INNO PHARMCHEM CO.,LTD. is a dedicated supplier of advanced chemical products, with a strong focus on pharmaceutical intermediates. Gefitinib, bearing the CAS number 184475-35-2, is a pivotal compound within our portfolio, essential for the synthesis of treatments targeting Non-Small Cell Lung Cancer (NSCLC). Our commitment to providing high-purity Gefitinib pharmaceutical intermediate supports the critical needs of the global pharmaceutical industry in developing effective cancer therapies.

The primary function of Gefitinib is that of a protein kinase inhibitor. It selectively targets and inhibits tyrosine kinases, such as the Epidermal Growth Factor Receptor (EGFR), which are often hyperactive in various cancers, including NSCLC. By disrupting these signaling pathways, Gefitinib offers a targeted therapeutic strategy that enhances treatment efficacy and patient outcomes. This precision is a hallmark of modern pharmaceutical innovation.

For manufacturers relying on precise chemical building blocks, the quality of Gefitinib CAS 184475-35-2 as a pharmaceutical intermediate is paramount. Chemically identified as N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine, it has a molecular formula C22H24ClFN4O3 and a molecular weight of 446.902. It is typically supplied as a white to beige powder, with a melting point of 119-120°C. NINGBO INNO PHARMCHEM CO.,LTD. ensures that each batch of our Gefitinib intermediate adheres to the strictest quality control standards, guaranteeing its suitability for sensitive pharmaceutical applications.

While Gefitinib therapy has proven effective, awareness of potential side effects is important. Clinical observations have noted transient elevations in serum aminotransferase levels and, on rare occasions, acute liver injury. This highlights the necessity for meticulous manufacturing processes and reliable sourcing of the Gefitinib pharmaceutical intermediate. Partnering with NINGBO INNO PHARMCHEM CO.,LTD. ensures that you receive a product manufactured under rigorous conditions, contributing to the overall safety and efficacy of the final drug product.

In conclusion, Gefitinib CAS 184475-35-2 is a critical component in the arsenal against lung cancer. Its role as a protein kinase inhibitor solidifies its importance in targeted therapy development. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to providing this high-quality pharmaceutical intermediate, thereby supporting advancements in medical treatments and contributing to better health outcomes for patients worldwide. Our focus remains on quality, reliability, and innovation in serving the pharmaceutical sector.